[1] Lee HW, Lee H, Kim BK, et al. Cost-effectiveness of chronic hepatitis C screening and treatment[J]. Clin Mol Hepatol,2022,28:164-173.
[2] Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression[J]. Hepatolog,y 2008,48:418-431.
[3] Westbrook RH, Dusheiko G. Natural history of hepatitis C[J]. J Hepatol,2014,61:S58-S68.
[4] Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C(genotype 1b) single-source outbreak in germany: A 20-year multicenter study[J]. Hepatology, 2000,32:91-96.
[5] Taha G, Ezra L, Abu-Freha N. Hepatitis C Elimination: Opportunities and Challenges in 2023[J]. Viruses,2023,15(7):1413.
[6] Kåberg M, Weiland O. Hepatitis C elimination-Macro-elimination[J]. Liver Int,2020,40:61-66.
[7] Wang AE, Hsieh E, Turner BJ, et al. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts[J]. J Gen Int Med, 2022,37:3435-3443.
[8] Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: Final update of the series[J]. J Hepatol,2020,73:1170-1218.
[9] Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C[J]. J Hepatol,2013;59:675-683.
[10] van der Meer AJ WH, Feld JJ, Dufour JF, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population[J]. JAMA,2014,312(18):1927-1928.
[11] Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study[J]. Hepatology,2018,67:2244-2253.
[12] Chang KC, Hung CH, Lu SN, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy[J]. J Antimicrob Chemother,2012,67:2766-2772.
[13] Huang CF, Yeh ML, Tsai PC, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication[J]. J Hepatol,2014,61:67-74.
[14] Pereira GH, Peixoto HR, Giusti ML, et al. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study[J]. Brazil J Infect Dis,2022,26(5):102697.
[15] Di Marco L, La Mantia C, Di Marco V. Hepatitis C: Standard of Treatment and What to Do for Global Elimination[J]. Viruses,2022,14(3):505.
[16] Schillie SWC, Osborne M, Wesolowski L, et al. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020[J]. MMWR Recomm Rep,2020, 69(2):1-17.
[17] Kondili LA, Andreoni M, Alberti A, et al. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression[J]. Epidemics,2021,34:100442.
[18] Panel AIHG. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection[J]. Clin Infect Dis,2018, 67(10):1477-1492.
[19] Calvaruso V, Craxì A. Hepatic benefits of HCV cure. J Hepatol,2020,73:1548-1556.
[20] Hagan LM, Kasradze A, Salyer SJ, et al. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination[J]. BMC Public Health,2019,19(Suppl 3):480.
[21] Pierce BG, Keck ZY, Foung SKH. Viral evasion and challenges of hepatitis C virus vaccine development[J]. Curr Opin Virol,2016,20:55-63. |
